Division of Hematology/Oncology


faculty photo

Donald Edward Tsai, M.D., Ph.D.

Associate Professor of Medicine at the Hospital of the University of Pennsylvania
Attending Physician, Hospital of the University of Pennsylvania, Philadelphia, PA
Department: Medicine

Contact information
Perelman Center for Advanced Medicine
2 West Pavilion
3400 Civic Center Boulevard
Philadelphia, PA 19104
Office: 215-614-0037
Fax: 215-615-5887
A.B. (Biochemistry)
Harvard College, Cambridge, MA, 1986.
Ph.D. (Microbiology & Immunology)
Duke University, Durham, NC, 1993.
M.D. (Medicine)
Duke University School of Medicine, Durham, NC, 1994.
Post-Graduate Training
Intern in Internal Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, 1994-1995.
Resident in Internal Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, 1995-1996.
Post doctoral Fellowship, Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, 1996-2000.
Internal Medicine, American Board of Internal Medicine, 1997.
Medical Oncology, American Board of Internal Medicine, 2001.
Medical Oncology Recertification, American Board of Internal Medicine, 2011.
Permanent link
> Perelman School of Medicine   > Faculty   > Details

Description of Research Expertise

Posttransplant Lymphoproliferative Disorder

Description of Clinical Expertise

Hematologic Malignancy and Stem Cell Transplantation

Selected Publications

Karuturi M, Shah N, Frank D, Fasan O, Reshef R, Ahya VN, Bromberg M, Faust T, Goral S, Schuster SJ, Stadtmauer EA, Tsai DE: Plasmacytic Posttransplant lymphoproliferative disorder: a case series of nine patients. Transplant International 26: 616-622, 2013.

Landsburg DJ, Stadtmauer E, Loren A, Goldstein S, Frey N, Nasta SD, Porter DL, Tsai DE, Perl AE, Hexner EO, Luger S: Receipt of maintenance therapy is most predictive of survival in older acute lymphoblastic leukemia patients treated with intensive induction chemotherapy regimens. American Journal of Hematology 88: 657-660, 2013.

Kremer BE, Reshef R, Misleh JG, Christie JD, Ahya VN, Blumenthal NP, Kotloff RM, Hadjiliadis D, Stadtmauer EA. Schuster SJ, Tsai DE. : Post-Transplant Lymphoproliferative Disorder Following Lung Transplantation: A Review of 35 Cases. Journal of Heart and Lung Transplantation 31: 296-304 2012.

Tizon R, Frey N, Heitjan DF, Tan KS, Goldsteind SC, Hexner EO, Loren A, Luger SM, Reshef R, Tsai D, Vogl D. Davis J, Vozniak M, Fuchs B, Stadtmauer EA, Porter DL: High dose corticosteroids with or without etanercept for the treatment of idiopathic pneumonia syndrome after allo-SCT. Bone Marrow Transplantation 2012 Notes: in press.

Lunardon L, Tsai KJ, Propert KJ, Fett N, Stanley JR, Werth VP, Tsai DE, Payne AS. : Adjuvant rituximab therapy of pemphigus: a single center experience with 31 patients. Archives of Dermatology 2012 Notes: in press.

Reshef R, Luskin MR, Kamoun M, Vardhanabhuti S, Tomaszewski JE, Stadtmauer EA, Porter DL, Heitjan DF, Tsai DE. : Association of HLA polymorphisms with post-transplant lymphoproliferative disorder in solid-organ transplant recipients. American Journal of Transplantation 11: 817-825, 2011.

Tsai DE, Chong E, Bagg A, Arnoldi S, Svoboda J, Nasta S, Schuster SJ. : Successful treatment of angioimmunoblastic T-cell lymphoma with the retinoic acid X receptor agonist, bexarotene. Leukemia & Lymphoma 52: 1815-1817, 2011.

Reshef R, Vardhanabhuti S, Luskin MR, Heitjan DF, Hadjiliadis D, Goral S, Krok KL, Goldberg LR, Porter DL, Stadtmauer EA, Tsai DE. : Reduction of immunosuppression as initial therapy for Posttransplant lymphoproliferative disorder. American Journal of Transplantation 11: 336-347, 2011.

Murashimo M, Milone M, Shaw LM, Tsai D, Bloom R: Methotrexate clearance by high-flux hemodialysis and peritoneal dialysis: a case report. American Journal of Kidney Diseases 2009 Notes: accepted.

Perl AE, Kasner MT, Tsai DE, Vogl DT, Loren AW, Schuster SJ, Porter DL, Stadtmauer EA, Goldstein SC, Frey NV, Nasta SD, Hexner EO, Dierov JK, Swider CR, Bagg A, Gewirtz AM, Carroll M, Luger SM: A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia. Clinical Cancer Research 15(21): 6732-9, 2009.

back to top
Last updated: 11/21/2013
The Trustees of the University of Pennsylvania

Clinical Briefings Blog Spot

Penn MD Forum title with Penn Medicine Shield and Twitter